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Longitudinal Strain Imaging in
Light-Chain Cardiac Amyloidosis
Can it Help to Refine
the Approach to Treatment?*
C. Cristina Quarta, MD, Rodney H. Falk, MD
Boston, Massachusetts
The systemic amyloidoses are a group of uncommon dis-
eases characterized by extracellular accumulation of fibrillar
proteins, leading to loss of normal tissue architecture and
function (1). Light-chain (AL) amyloidosis, which is prob-
ably the most frequent form, can potentially involve any
organ, but when the heart is affected, the outcome is
particularly poor, with a median survival of 4 to 6 months
(2). Over the past few years, the chemotherapeutic options
for treating AL amyloidosis have expanded considerably,
but the more aggressive therapies, such as high-dose mel-
phalan with autologous stem cell transplantation, are lim-
ited in many patients with cardiac involvement (3,4).
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It is therefore essential to carefully address the risk-benefit
profile of the various therapies when faced with a therapeu-
tic decision in AL amyloidosis, because aggressive therapies,
although possibly associated with a higher remission rate,
can result in early treatment-related mortality if cardiac
involvement is present.
Myocardial strain echocardiography is a sensitive tool for
studying left ventricular (LV) function in many cardiac
diseases, including cardiac amyloidosis. Early studies, using
Doppler-derived strain and strain rate imaging, found that
global longitudinal deformation was more sensitive in de-
tecting early systolic dysfunction than was standard tissue
Doppler imaging (5). Subsequent studies showed the supe-
rior prognostic value of strain imaging, but these did not
evaluate the relative prognosis of strain imaging over stan-
dard non-Doppler parameters (6). In their large cohort of
patients with AL amyloidosis, Buss et al. (7), in this issue of
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strain imaging, a technique that is simpler to use and more
reproducible than Doppler-derived strain imaging. In a
multivariate analysis, they confirmed that reduced LV lon-
gitudinal function is an independent predictor of survival,
but they also showed that it appears to offer incremental
information beyond both standard clinical parameters and
commonly used prognostic serological parameters in AL
amyloidosis, specifically serum troponin and N-terminal
pro–B-type natriuretic peptide (NT-proBNP).
The study has several strengths, but it also has important
limitations that are worthy of consideration before the
results can be put into clinical practice. As pointed out by
the investigators, all the imaging analyses were done with a
single system. Although this is appropriate for such a study,
there is considerable inter-manufacturer variability and lack
of standardization for strain imaging, both using two-
dimensional speckle tracking and the newer three-
dimensional systems (8). Thus, the investigators’ cutoff
values for determining prognosis are only of value when
obtained by the analysis equipment that they used, and
cannot be extrapolated to other systems until validated
across different analysis platforms. Perhaps more important
is the manner in which the data were collected. Although
referred to as a “prospective observational study,” the col-
lection of the echocardiographic, clinical, and biochemical
measurements, was obtained at the patient visits, whereas
the analysis was performed retrospectively. Thus, the
speckle tracking strain parameters determined to be optimal
for separating survivors from nonsurvivors still need to be
validated in a prospective study of untreated patients.
In addition to analyzing the whole cohort, the investiga-
tors looked at subgroups and concluded that their cutoff
parameters remained robust, both among patients who had
not been previously treated and in those with an ejection
fraction (EF)  50% and 50%, respectively. EF in cardiac
amyloidosis may be near-normal until late in the disease,
even if significant heart failure is present, and impaired
longitudinal strain in such patients underscores that there is
a definite systolic component to heart failure even in the
presence of a normal EF. It is critical to recognize, however,
that the group of patients with the normal and/or near-
normal EF was not homogenous, because this study was not
limited to patients with AL amyloidosis involving the heart,
but included any patient with AL amyloidosis of any organ
evaluated at the investigators’ institution. As such, those
with a normal EF might or might not have had cardiac
amyloidosis. Because the presence of cardiac involvement in
AL amyloidosis is an adverse prognostic factor, one would
anticipate that an abnormal longitudinal strain would be
associated with a worse prognosis in this group, as it simply
identifies patients with cardiac amyloidosis as opposed to
those free of heart involvement. Strain imaging analysis of
patients with an EF 50% and evidence by other criteria
1078 Quarta and Falk JACC Vol. 60, No. 12, 2012
Strain Imaging in Cardiac Amyloidosis September 18, 2012:1077–8of cardiac involvement was not reported, but would be of
interest.
Despite these shortcomings, the paper by Buss et al. (7)
provides new insights into the mechanisms of LV dysfunc-
tion in cardiac amyloidosis. Both NT-proBNP and cardiac
troponin are accepted as useful markers of prognosis in AL
amyloidosis (9), and NT-proBNP elevation may reflect
more than simply an increased ventricular wall stress due to
high filling pressures (10). The investigators found a strong
correlation between NT-proBNP levels and longitudinal
strain values, with a weaker correlation with troponin levels.
However, in multivariate analysis, NT-proBNP was no
longer a prognostic factor, whereas longitudinal strain and
troponin levels remained significant. The association of
myocardial strain values with NT-proBNP has been noted
in other cardiac diseases, and raises some intriguing avenues
for future research (11). It is now well recognized that a
hematologic response to chemotherapy in AL amyloidosis is
associated with an early decrease in NT-proBNP in associ-
ation with clinical improvement, even when wall thickness
remains unchanged. These data raise the possibility that
improvement in longitudinal strain may be an early feature
of hematologic remission. As hematologic remission is
defined as normalization of elevated free serum light chains
and, because the latter have been shown to be cardiotoxic in
vitro, strain imaging might turn out be a sensitive marker of
changes in cardiac function related to chemotherapy. It has
the potential to give insight into mechanisms of clinical
improvement after chemotherapy if improved strain corre-
lates with normalization of an abnormal free light chain
ratio.
Finally, it should be recognized that treatment in AL
cardiac amyloidosis is a fast-moving field, and a once
universally fatal disease is now treatable, with long-term
remission and a good quality of life achievable in many
patients if they are treated in skilled centers. Although the
investigators did not give details of the therapy used in their
patients, they mentioned high-dose chemotherapy with
autologous stem cell transplant, which, although highly
effective in some patients, carries a high mortality rate when
used in patients with AL amyloidosis involving the heart
(3). Since 2008, when their study enrollment ended, there
has been increasing use of bortezomib-based regimens for
the treatment of AL amyloidosis, with evidence that it is
well tolerated in cardiac amyloidosis; potentially 40% of
previously untreated patients can achieve a relatively rapid
hematologic remission (12). This therapy may, therefore,
represent an advance over current therapies for AL amy-
loidosis involving the heart. Whether the use of bortezomib
as an early or first-line therapy in AL cardiac amyloidosiswill affect the potential prognostic value of strain imaging
remains to be seen, and will require further study.
Given these limitations, and the changing face of cardiac
amyloidosis treatment, it is unlikely that the strain values
described in this paper will show prognostic value if applied
exactly as defined. However, the observations are interesting
and demonstrate that with further refinement, LV longitu-
dinal strain is likely to be integrated in the therapeutic
decision making and, eventually, the evaluation of the
response to treatment of this serious, but now treatable,
disease.
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